Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This study investigates the suitability of a hybrid system combining membrane filtration and ozone oxidation for efficiently treating pharmaceuticals and personal care products (PPCPs) in hospital wastewater. Two feedstocks, untreated (F-1) and biologically treated wastewater (F-2), were used to determine the optimal system location for maximizing PPCPs reduction. F-2 application was found to be more effective based on the observed reaction rate constant, membrane performance, and structural transitions. The cleaning chemicals and foulant layer formation caused structural changes in both the PAN and α-AlO membranes. Moreover, contact angle measurements confirmed that increased hydrophobicity induced contaminant attraction and decreased the membrane flux. Performance evaluation results revealed 77.87 % (PAN) and 74.13 % (α-AlO) reductions in total organic carbon from F-2. The decrease in membrane flux was observed in the following order: α-AlO (F-1) > PAN (F-1) > PAN (F-2) > α- AlO (F-2). Pseudo-first-order fitting confirmed that the degradation rate constants (k) were higher under the F-2 exposure conditions. The order of degradation rate is carbamazepine > trimethoprim > atenolol > acetaminophen > sulfamethoxazole > caffeine. Analysis of degradation pathways and toxicity suggests that transformation products formed during membrane + O/UV hybridized process are environmentally benign and do not pose significant health risks.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhazmat.2025.138804DOI Listing

Publication Analysis

Top Keywords

performance evaluation
8
hybrid system
8
personal care
8
care products
8
products ppcps
8
hospital wastewater
8
membrane flux
8
f-1 > pan
8
degradation rate
8
membrane
6

Similar Publications

Background: Owing to the unique characteristics of digital health interventions (DHIs), a tailored approach to economic evaluation is needed-one that is distinct from that used for pharmacotherapy. However, the absence of clear guidelines in this area is a substantial gap in the evaluation framework.

Objective: This study aims to systematically review and compare the economic evaluation literature on DHIs and pharmacotherapy for the treatment of depression.

View Article and Find Full Text PDF

Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.

View Article and Find Full Text PDF

Background: Peripheral nerve injury commonly results in pain and long-term disability for patients. Recovery after in-continuity stretch or crush injury remains inherently unpredictable. However, surgical intervention yields the most favorable outcomes when performed shortly after injury.

View Article and Find Full Text PDF

BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.

View Article and Find Full Text PDF

Importance: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need.

Objective: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial.

View Article and Find Full Text PDF